| 摘要 |
<p>This invention relates to novel fused tricyclic compounds that are inhibitors of mammalian Target of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP, and are useful in the treatment of cellular proliferative diseases, for example cancer and other proliferative disorders.</p> |
| 申请人 |
SCHERING CORPORATION;MENG, ZHAOYANG;REDDY, PANDURANGA ADULLA, P.;SIDDIQUI, M. ARSHAD;MANDAL, AMIT, K.;LIU, DUAN;ZHAO, LIANYUN;MCRINER, ANDREW |
发明人 |
MENG, ZHAOYANG;REDDY, PANDURANGA ADULLA, P.;SIDDIQUI, M. ARSHAD;MANDAL, AMIT, K.;LIU, DUAN;ZHAO, LIANYUN;MCRINER, ANDREW |
